MAPK14 and posterior cortical atrophy: To establish a preclinical proof-of-principle in the in vivo mouse model, we first established the in vivo PDX-PCa mouse model in six mice, and results revealed that mice receiving Enz (30 mg/kg/every other day) had an increase in MAO-A, ARv7, and p-p38 level in the xenografted PDX tumors (Fig. 6a).